Regardless of how this works out, someone at ITMN is getting plaudits for having ensured that ITMN collects milestones and royalties from Roche for any HCV PI that Roche decides to develop.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”